DHL Supply Chain is to acquire final-mile delivery and healthcare transportation specialist SDS Rx, subject to regulatory approvals. The company delivers from more than 200 locations across the US. The acquisition also expands DHL’s same-day and expedited delivery capabilities for life sciences and healthcare customers. It follows DHL’s purchase of CryoPDP, a leading specialty courier focused on clinical trials and biopharmaceuticals earlier this year.
Chief executive of DHL Supply Chain North America, Mark Kunar, said: “The life sciences and healthcare sector is projected to grow at a compound annual growth rate of 11% through 2030. Specialty pharmacy already accounts for approximately 50% of total prescription drug spending in the U.S., and the number of patients served by specialty pharmacies grew by 12% between 2018 and 20221.
“The increasing demand for specialty pharma and healthcare solutions presents significant opportunities for DHL to leverage its scale, expertise, and commitment to operational excellence. With this acquisition, we are expanding our healthcare logistics capabilities, attracting a new segment of healthcare customers, and reinforcing our position as a trusted partner in building resilient and connected healthcare supply chains.”
